SLC5A2 and diabetes mellitus: A shift in diabetes management from a glucocentric approach to one more focused on reducing these complications was facilitated by the rapid emergence of novel effective medications, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) [8].